CHMP recommends approval for Janssen's mAb in psoriatic arthritis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for the expanded use of guselkumab (Tremfya), a monoclonal antibody (mAb) from the Janssen Pharmaceutical Companies of Johnson & Johnson.
CHMP recommends Alnylam's RNAi therapeutic for approval
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) posted a positive opinion recommending approval for Alnylam Pharmaceutical's lumasiran, an investigational RNA interference (RNAi) therapeutic for the treatment of primary hyperoxaluria type 1.
NIH initiates ACTIV trial for COVID-19 immune modulators
The U.S. National Institutes of Health (NIH) has launched an adaptive phase III trial called Accelerating COVID-19 Therapeutics Interventions and Vaccines (ACTIV)-1 Immune Modulators, which is evaluating the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19.
Precigen nabs FDA nod for manufacturing UltraCAR-T therapies
Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology transfer to clinical sites and will be used as a manufacturing device for Precigen's investigational UltraCAR-T therapies.
Thermo Fisher launches closed cell processing system
Thermo Fisher Scientific has launched the Gibco CTS Rotea counterflow centrifugation system, a modular, closed cell therapy processing system for cell therapy development and manufacturing.
Castle Creek begins gene therapy clinical trial for scleroderma
Castle Creek Biosciences has initiated a phase I/II clinical trial evaluating FCX-013, the company's investigational gene therapy for the treatment of moderate to severe localized scleroderma.
ImmunityBio begins phase I trial for its COVID-19 vaccine candidate
ImmunityBio has been authorized by the U.S. Food and Drug Administration to begin a phase I clinical trial of its hAd5-COVID-19 vaccine candidate.
Eiger touts positive results for COVID-19 therapy
Eiger BioPharmaceuticals is touting positive clinical results from a study conducted at the University of Toronto for its COVID-19 immunotherapy, peginterferon lambda (Lambda).
Cellaria introduces new models to study pancreatic cancer
Cellaria has launched three new cell lines for pancreatic cancer that it hopes will improve patient care by improving the value of in vitro methods of developing therapies.
Sestina Bio to develop digital cell engineering platform
Sestina Bio, a new company developing an automated synthetic biology platform, has been launched with seed funding. Sestina also is the first company to be launched from the Foresite Labs incubator.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter